NCT07281937

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 206 (actual)
• Sponsor: Verdiva Bio Dev Limited · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.

Detailed description

This is a randomized, double-blind, placebo-controlled study of oral ecnoglutide (VRB-101), with 5 active arms and 1 placebo arm. The study will include a Screening Period of 4 weeks, followed by a 20-week Study Treatment Period and a 4-week Safety Follow-up Period prior to the end of study (EOS) visit.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	VRB-101	VRB-101 tablets will be administered orally.
DRUG	Placebo	Placebo tablets will be administered orally.

Timeline

• Start date: 2025-11-25
• Primary completion: 2026-07-01
• Completion: 2026-08-01
• First posted: 2025-12-15
• Last updated: 2026-03-18

Locations

22 sites across 1 country: United States

Regulatory

• FDA-regulated drug study